Nucleic Acid Therapeutics Initiative (NATi)

Looking for R&D Career Opportunities in the Nucleic Acid Therapeutics Space in Singapore? Be sure to send us your CV or resume to be notified if any positions are made available! Drop your CV or resume here: https://lnkd.in/gyScWihd Mohamed ElSayed, Ph.D. | Xi (Sissi) Lin #CareerOpportunities #NucleicAcidTherapeutics #RNAdrugdevelopment #mRNA #oligonucleotides #oligo

🌟 Happy New Year! 🌟 As we welcome 2025, we look forward yet another year of RNA drug discovery and development. 2025 will be another year abound with innovation, growth, opportunities and challenges. Wishing you all a prosperous and inspiring year ahead! 🚀 #HappyNewYear #2024Goals #Innovation #Collaboration #FutureFocused

🎄✨ Happy Holidays from NATi! 🎉 As we approach the festive season, we want to take a moment to express our gratitude for our incredible team, industry partners and ecosystem partners. Wishing everyone a joyful and restful holiday season. Here’s to a successful 2024! 🌟 #HappyHolidays #TeamSpirit #Gratitude #MerryChristmas

Looking forward to the collaboration with SCG Cell Therapy and A*STAR Bioprocessing Technology Institute (BTI) to develop innovative RNA medicines and develop Singapore into a regional hub for nucleic acid therapeutics. #RNAmedicines #RNAdrugs #mRNAvaccines #therapeutics #innovation #nucleicacidtherapeutics

🔬 Exploring the Future of Nucleic Acid Therapeutics at NPMA 🔬    We are excited to share that Dr Mohamed ElSayed, Ph.D. was invited to speak at the National Precision Medicine Alliance (NPMA) meeting organised by the A*STAR Genome Institute of Singapore (A*STAR GIS) where he shared about NATi's perspective on the challenges and opportunities in the development of nucleic acid therapeutics.   The future of medicine is precision-driven, and NATi is committed to advancing the development of cutting-edge solutions that can transform patient care. Looking forward to further conversations with innovators in this space!   #NucleicAcidTherapeutics #mRNA #Innovation #RNATherapeutics #Biotech #NPMA2024

🧬Delivering on the promise of RNA therapeutics NATi CSO Dr Mohamed ElSayed, Ph.D. was part of a panel, Unlocking The Clinical Potential of RNA Therapeutics with Targeted Delivery, at the recent inaugural Asia DDF Summit (Drug Delivery & Formulation) Summit 🌏. He shared on how there is a need to develop delivery solutions to allow drug hunters to access new tissues and cells to expand on the diseases that can be tackled by RNA therapeutics. There remains a strong need for specificity in delivering the drugs to the right places. His fellow panelists, Prof Khuloud Al-Jamal, Dr Pierre Wils, and Dr. VAIBHAV DUBEY, moderated by Dr. Ajay Singh. The exciting panel covered a range of topics from manufacturability to greater access to mRNA medicines for all. Also at the Asia DDF Summit 2024, Prof Huck Hui Ng presented on Building and Scaling RNA Therapeutics and Manufacturing Capabilities in Singapore. He spoke about the progress Singapore has made in developing cutting-edge nucleic acid therapeutics 🧬, building state-of-the-art manufacturing capabilities 🏭, and fostering collaborative ecosystems 🤝 that bridge science and industry. Missed out on the recent talks? Be sure to follow us on LinkedIn and keep an eye out for our next events. #Innovation #RNATherapeutics #DrugDelivery #Manufacturing #PromiseOfRNA #mRNA #ASO #siRNA #RNAi

Pioneering mRNA Innovation in Asia with Quantoom Biosciences’ Ntensify® midi! 🇸🇬💉 ➥https://shorturl.at/ENNNZ ➥https://shorturl.at/ZI2Vl We’re thrilled to see the launch of the NATi mRNA BioFoundry, Asia’s first dedicated mRNA production laboratory, aimed at bolstering pandemic preparedness and advancing mRNA therapeutics. This state-of-the-art facility, a collaboration between A*Star (part of A*STAR Bioprocessing Technology Institute (BTI), led by Boon Tong Koh , Executive Director, and Andre Choo , Deputy Executive Director), NATi, and R3 program (part of Wellcome Leap - led by Duccio Medini, PhD, R3 Program Director) , leverages our Ntensify® midi system to automate and accelerate mRNA production, significantly reducing the time required to produce high-quality RNA for pre-clinical research.   With the capacity to produce up to 5g of purified RNA daily—enough for 100,000 vaccine doses—this facility stands ready to respond swiftly to future health crises, as well as support research into mRNA-based treatments for cancer, cardiovascular diseases, and more.   It’s an honor for Quantoom Biosciences to contribute to Singapore’s vision of becoming a leading hub for biomedical innovation. Together, we’re empowering a new era of healthcare resilience and biomanufacturing capability in the region!   #mRNA #PandemicPreparedness #Biomanufacturing #BiomedicalInnovation #QuantoomBiosciences #NucleicAcidTherapeutics #Singapore #AStar #WellcomeLeap

𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝗶𝗻𝗴 𝗦𝗶𝗻𝗴𝗮𝗽𝗼𝗿𝗲'𝘀 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻 𝗶𝗻 𝗺𝗥𝗡𝗔 𝗮𝗻𝗱 𝗡𝘂𝗰𝗹𝗲𝗶𝗰 𝗔𝗰𝗶𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 “The NATi mRNA BioFoundry demonstrates Singapore’s commitment to building critical infrastructure for nucleic acid drug development and future pandemic preparedness.” – Dr Boon Tong Koh, Executive Director, A*STAR A*STAR Bioprocessing Technology Institute (BTI) & Nucleic Acid Therapeutics Initiative (NATi) The newly launched NATi mRNA BioFoundry is the first-of-its-kind in Asia, designed to accelerate #mRNA manufacturing and nucleic acid therapeutics research. By integrating advanced automation, it will enhance pandemic preparedness and streamline production, allowing faster breakthroughs in research and commercialisation. The BioFoundry is built in collaboration between NATi, A*STAR, and Wellcome Leap. Read on to discover how NATi mRNA BioFoundry can benefit the biomedical sector. 🔗 Visit: https://lnkd.in/g8YHZRCN #Innovation #Biotech #Healthcare #EnhancingLives #Singapore

🎉 Event Recap: In Conversation with Dr. Frank Bennett from Ionis Pharmaceuticals! 🎉 It was a privilege to host Dr. Frank Bennett, Ph.D., a pioneer in RNA therapeutics and antisense oligonucleotides (ASOs). He shared about the incredible potential of ASOs for treating a variety of genetic diseases, including spinal muscular atrophy and beyond. These life changing drugs have had profound impact on patients lives and continue to do so. Dr. Bennett shared how Ionis Pharmaceuticals is also exploring delivering ASOs to tissues and cells beyond the liver and CNS, potentially through use of novel ligands. This approach offers hope for patients with conditions once thought to be untreatable. As Singapore continues to expand its RNA drug development capabilities, discussions like this underscore our commitment to supporting cutting-edge therapies that have the power to transform lives. Stay tuned as NATi brings you more events as well as further collaborations and advancements in the nucleic acid therapeutics space! #NATi_sg #AntisenseOligonucleotides #RNAtherapeutics #PrecisionMedicine #SingaporeBiotech #InnovativeMedicine #Pharma

Nucleic Acid Therapeutics Initiative (NATi) would like to thank Minister Dr Tan See Leng for his support on the official launch of the non-GMP NATi mRNA BioFoundry (hosted by A*STAR - Agency for Science, Technology and Research). The BioFoundry will help support preclinical studies using mRNA as a drug modality. If you are looking for a partner to help bring RNA medicines from bench to clinic, do reach out to enquiry@nati.sg for potential collaborations. #mRNA #biofoundry #automatedmRNAsynthesis #mRNAdrugs ------ You can find out more about this first-in-its-kind BioFoundry in Asia on the Straits Times coverage here: https://lnkd.in/gnKWERyU